[AsCNP_P22] ポスター22
Schizophrenia 1

[AsCNP-P22-6] Clinical Global Impression of Severity after aripiprazole once-monthly versus paliperidone palmitate once-monthly and the effects observed in patients with schizophrenia stratified by disease severity: a post-hoc analysis of QUALIFY

^○Ross BAKER¹, Simon Nitschky SCHMIDT², Pedro SUCH², Peter HERTEL², Jessica MADERA¹ (1. Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, USA, 2. H. Lundbeck A/S, Valby, Denmark)